8-K
filed May 21, 2026, 4:07 PM ET
ticker TVTX
CIK 0001438533
other material
confidence high
sentiment neutral
materiality 0.60
Travere shareholders approve 3M share increase under 2018 equity plan
Travere Therapeutics, Inc.
- Stockholders approved amendment to 2018 Plan, increasing authorized shares by 3,000,000 shares.
- Ten directors elected to serve until 2027 annual meeting; all received majority votes.
- Advisory say-on-pay resolution passed with 73.7M votes for (97.3% of votes cast).
- Shareholders ratified Ernst & Young as independent auditor for fiscal year 2026.
- Annual meeting held May 19, 2026; 81.1M shares (88% of outstanding) were represented.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Travere Therapeutics, Inc. shareholders approved Approval of the Company's 2018 Equity Incentive Plan, as amended at the 2026-05-19 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-19
Exact text from the filing
Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. The final voting results are as follows: Votes For 72,998,395 Votes Against 2,787,402 Abstentions 32,347 Broker Non-Votes 5,290,327
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company's named executive officers at the 2026-05-19 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-19
Exact text from the filing
Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows: Votes For 73,711,670 Votes Against 2,073,324 Abstentions 33,152 Broker Non-Votes 5,290,327
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-19 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-19
Exact text from the filing
The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2027 Annual Meeting of Stockholders. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Roy D. Baynes, M.D., Ph.D. 66,479,999 9,338,149 5,290,327 Suzanne Bruhn, Ph.D. 74,711,994 1,106,154 5,290,327 Timothy Coughlin 73,695,965 2,122,183 5,290,327 Eric Dube, Ph.D. 75,095,860 722,288 5,290,327 Gary Lyons 74,208,952 1,609,196 5,290,327 Jeffrey Meckler 73,469,263 2,348,885 5,290,327 John A. Orwin 74,657,472 1,160,676 5,290,327 Sandra Poole 74,551,138 1,267,010 5,290,327 Ron Squarer 74,767,455 1,050,693 5,290,327 Ruth Williams-Brinkley 74,764,679 1,053,469 5,290,327
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Travere Therapeutics, Inc. shareholders approved Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-05-19 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-05-19
Exact text from the filing
Proposal 4: Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers The Company’s stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: One Year 75,003,558 Two Years 4,996 Three Years 766,756 Abstentions 42,836 Broker Non-Votes 5,290,327
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-05-19 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-19
Exact text from the filing
Proposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For 80,708,265 Votes Against 120,699 Abstentions 279,509 Broker Non-Votes —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.